Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

QURE

uniQure N.V

Dec 12 • 04:00PM ET

19.51

-0.24 -1.22 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: SRPT BLUE CRSP BMRN NTLA SGMO RCKT EDIT ADVM BOLD

| Held by: VXF XBI VHT IBB SCHA JGRO LABU ITOT KOMP SCHB

Index	-	P/E	-	EPS (ttm)	-4.39	Insider Own	7.85%	Shs Outstand	62.17M	Perf Week	-8.53%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-3.21	Insider Trans	-6.51%	Shs Float	56.77M	Perf Month	-35.23%
Enterprise Value	1.04B	PEG	-	EPS next Q	-0.92	Inst Own	89.81%	Short Float	14.68%	Perf Quarter	31.51%
Income	-235.15M	P/S	76.31	EPS this Y	21.17%	Inst Trans	-6.74%	Short Ratio	1.77	Perf Half Y	27.18%
Sales	15.75M	P/B	5.30	EPS next Y	17.11%	ROA	-30.65%	Short Interest	8.34M	Perf YTD	10.48%
Book/sh	3.68	P/C	1.73	EPS next 5Y	27.45%	ROE	-165.27%	52W High	71.50 -72.71%	Perf Year	27.52%
Cash/sh	11.27	P/FCF	-	EPS past 3/5Y	- -9.66%	ROIC	-31.08%	52W Low	7.76 151.42%	Perf 3Y	-17.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-62.73% 30.08%	Gross Margin	-14.37%	Volatility	4.91% 7.23%	Perf 5Y	-58.72%
Dividend TTM	-	EV/Sales	65.99	EPS Y/Y TTM	11.49%	Oper. Margin	-1225.66%	ATR (14)	2.58	Perf 10Y	4.39%
Dividend Ex-Date	-	Quick Ratio	7.12	Sales Y/Y TTM	-44.90%	Profit Margin	-1492.90%	RSI (14)	24.43	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	7.12	EPS Q/Q	-51.08%	SMA20	-23.17%	Beta	0.67	Target Price	52.55
Payout	-	Debt/Eq	2.32	Sales Q/Q	61.83%	SMA50	-53.00%	Rel Volume	0.39	Prev Close	19.75
Employees	209	LT Debt/Eq	2.31	Earnings	Nov 10 BMO	SMA200	-12.65%	Avg Volume	4.72M	Price	19.51
IPO	Feb 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-52.86% -36.10%	Trades		Volume	1,850,236	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Downgrade	William Blair	Outperform → Mkt Perform
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78
Apr-01-21	Upgrade	Mizuho	Neutral → Buy	$52
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-24-20	Initiated	H.C. Wainwright	Buy	$80
Nov-11-20	Initiated	Berenberg	Buy
Nov-09-20	Initiated	Jefferies	Buy	$55
Nov-04-20	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$61
Aug-25-20	Initiated	Raymond James	Strong Buy	$75
Jul-31-20	Upgrade	Robert W. Baird	Neutral → Outperform	$57

Show Previous Ratings

Dec-04-25 12:18PM	uniQure N.V. (QURE): A Bear Case Theory (Insider Monkey) -10.75%
10:02AM	UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy (Investor's Business Daily)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty (Insider Monkey)
Nov-19-25 08:16AM	Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 (Insider Monkey) -5.92%
12:15PM	Loading…
Nov-17-25 12:15PM	Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA (Insider Monkey)
Nov-12-25 07:00AM	uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences (Insider Monkey)
Nov-10-25 04:01PM	uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges (GuruFocus.com) -5.90% +17.93%
08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:14AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:05AM	uniQure to Announce Third Quarter 2025 Financial Results (GlobeNewswire) +5.56%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -14.39%
Nov-04-25 01:36PM	FDA halts uniQures plans for Huntingtons disease gene therapy (Pharmaceutical Technology) -11.23%
Nov-03-25 04:29PM	These Stocks Moved the Most Today: Kenvue, Kimberly-Clark, Amazon, uniQure, Palantir, Idexx, Cipher Mining, and More (Barrons.com) -49.34%
04:27PM	Loading…
04:27PM	UniQure Plummets 49% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy (Investor's Business Daily)
11:15AM	uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results (Insider Monkey)
08:33AM	UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. (Barrons.com)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Oct-30-25 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:00AM	uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 04:58PM	uniQure N.V. (QURE): A Bull Case Theory (Insider Monkey) -5.01%
Oct-19-25 03:09AM	H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating (Insider Monkey)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 05:34AM	Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here" (Insider Monkey)
Oct-03-25 04:14PM	QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop (MarketBeat)
Sep-30-25 12:46PM	uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission (Insider Monkey)
Sep-29-25 06:28PM	uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment (Insider Monkey) +9.37%
04:05PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
11:38PM	Loading…
Sep-25-25 11:38PM	uniQure Announces Pricing of Upsized $300 Million Public Offering (GlobeNewswire) +10.84%
11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:23AM	Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington's Disease (Insider Monkey)
09:36AM	Stocks to Watch Thursday: Intel, Oracle, CarMax, Accenture (The Wall Street Journal)
09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 04:37PM	Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it (MarketWatch) +247.73%
04:21PM	A Cure For Huntington's Disease? UniQure Launches Nearly 250%. (Investor's Business Daily)
04:06PM	uniQure Announces $200 Million Proposed Public Offering (GlobeNewswire)
10:23AM	uniQure Stock Doubles On Promising Data From Huntington's Disease Trial (Benzinga)
07:10AM	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding (GlobeNewswire)
07:05AM	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-05-25 07:05AM	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Jul-31-25 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet (Zacks)
Jul-29-25 08:15AM	uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.68%
07:13AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
Jul-22-25 07:05AM	uniQure to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-23-25 01:38AM	Lake Street: AMT-130 Could Be Game-Changer For ClearPoint (Insider Monkey)
Jun-11-25 08:00AM	uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer (GlobeNewswire)
Jun-04-25 08:55AM	Lake Street says AMT-130 could be significantly impactful for ClearPoint (TipRanks)
Jun-02-25 07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
May-29-25 07:05AM	uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +7.37%
May-14-25 09:55AM	Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? (Zacks)
May-10-25 03:04AM	uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:18AM	UniQure: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
May-05-25 04:05PM	uniQure to Announce First Quarter 2025 Financial Results (GlobeNewswire) +7.58% -27.75%
Apr-30-25 05:10AM	Deep Sail Capital Partner Q1 2025 Investor Letter (Seeking Alpha) +6.49%
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
Apr-21-25 09:54AM	uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? (Zacks)
08:54AM	FDA grants breakthrough status to uniQures Huntingtons disease therapy (Pharmaceutical Technology)
07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
01:56AM	uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130 (Seeking Alpha)
Apr-19-25 08:31AM	uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting (Seeking Alpha)
Apr-17-25 07:17AM	uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease (GlobeNewswire) +38.45%
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Feb-27-25 08:35AM	UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:05AM	uniQure Announces 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-07-25 01:04PM	uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years (Benzinga) -9.75%
09:12AM	CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B (PR Newswire)
Feb-03-25 07:05AM	uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease (GlobeNewswire)
Jan-30-25 07:37AM	uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS (GlobeNewswire)
Jan-27-25 05:14PM	Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts? (Insider Monkey)
Jan-13-25 04:17PM	Heres Why uniQure N.V. (QURE) Is Skyrocketing (Insider Monkey)
Jan-11-25 08:01PM	Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? (Insider Monkey)
Jan-08-25 07:05AM	uniQure Announces Pricing of its Public Offering (GlobeNewswire) -9.75%
Jan-07-25 04:49PM	uniQure Announces Proposed Public Offering (GlobeNewswire)
Dec-17-24 07:20AM	uniQure price target raised to $32 from $12 at Stifel (TipRanks) -5.40%
Dec-15-24 04:31AM	Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? (Motley Fool)
Dec-10-24 05:11PM	UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily) +109.73%
09:34AM	UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug (Investor's Business Daily)
07:07AM	UniQure shares soar on chance of speedy approval for Huntingtons therapy (BioPharma Dive)
07:05AM	uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease (GlobeNewswire)
Nov-29-24 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet (Zacks)
Nov-28-24 12:00PM	What Makes uniQure (QURE) a New Buy Stock (Zacks)
Nov-21-24 07:05AM	uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Nov-08-24 09:55AM	Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade (Zacks)
Nov-05-24 08:30AM	UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +8.99%
07:26AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-29-24 10:01AM	UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-24 03:03PM	State Street Corp's Strategic Reduction in uniQure NV Holdings (GuruFocus.com)
Oct-15-24 07:05AM	uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS (GlobeNewswire)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gut Robert	Director	Nov 06 '25	Option Exercise	4.57	15,840	72,389	71,579	Nov 10 04:54 PM
Gut Robert	Director	Nov 06 '25	Sale	27.26	31,434	856,881	40,145	Nov 10 04:54 PM
Kaye Jack	Director	Nov 04 '25	Option Exercise	9.88	38,810	383,535	38,249	Nov 06 05:01 PM
Kaye Jack	Director	Nov 04 '25	Sale	30.34	38,810	1,177,517	20,439	Nov 06 05:01 PM
Gut Robert	Director	Nov 06 '25	Proposed Sale	26.06	31,434	819,170		Nov 06 04:13 PM
Kaye Jack	Director	Nov 04 '25	Proposed Sale	34.29	38,810	1,330,794		Nov 04 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Option Exercise	6.52	226,316	1,474,909	877,770	Sep 26 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Sale	41.46	226,316	9,382,473	651,454	Sep 26 07:43 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Option Exercise	5.37	15,000	80,550	232,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Option Exercise	13.03	3,000	39,090	220,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Sale	55.00	15,000	825,000	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Sale	40.04	3,000	120,120	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Officer	Sep 26 '25	Proposed Sale	55.00	15,000	825,000		Sep 26 04:04 PM
KLEMT CHRISTIAN	Officer	Sep 24 '25	Proposed Sale	40.00	3,000	120,000		Sep 24 08:01 PM
Kapusta Matthew C	Director	Sep 24 '25	Proposed Sale	41.45	226,316	9,381,750		Sep 24 07:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 27 '25	Sale	13.92	1,466	20,407	150,437	Jul 01 04:49 PM
Springhorn Jeremy P.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,694	Jun 24 06:08 PM
POST LEONARD E	Director	Jun 20 '25	Sale	14.45	2,112	30,518	29,937	Jun 24 06:03 PM
Kaye Jack	Director	Jun 20 '25	Sale	14.45	2,112	30,518	20,439	Jun 24 05:53 PM
Jacques Rachelle Suzanne	Director	Jun 20 '25	Sale	14.45	2,112	30,518	28,346	Jun 24 05:50 PM
Gut Robert	Director	Jun 20 '25	Sale	14.45	3,336	48,205	56,879	Jun 24 05:45 PM
Balachandran Madhavan	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,697	Jun 24 05:42 PM
Meek David D.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	34,190	Jun 24 05:34 PM
Potts Jeannette	Chief Legal Officer	Jun 16 '25	Sale	15.14	4,670	70,704	115,073	Jun 20 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Mar 04 '25	Sale	10.29	28,341	291,629	651,454	Mar 05 05:32 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '25	Sale	10.29	1,350	13,891	151,903	Mar 05 05:28 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '25	Sale	10.29	10,438	107,407	217,730	Mar 05 05:25 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '25	Sale	10.29	7,076	72,812	119,743	Mar 05 05:21 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '25	Sale	10.70	26,727	285,979	571,188	Feb 27 07:33 PM
Kapusta Matthew C	CEO, Managing Director	Feb 27 '25	Sale	11.32	6,717	76,036	580,795	Feb 27 07:33 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '25	Sale	10.70	14,341	153,449	152,372	Feb 27 07:29 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 27 '25	Sale	11.32	2,916	33,009	155,168	Feb 27 07:29 PM

Open in Screener

CGON

Cg Oncology Inc

Dec 12 • 04:00PM ET

40.94

-0.67 -1.61 %

Healthcare • Biotechnology • USA • NASD

Peers: ONC BPMC EXEL PTCT PBYI FATE KURA MGNX GERN IMMP

| Held by: VTI VB IWM VBR XBI VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.98	Insider Own	39.33%	Shs Outstand	78.28M	Perf Week	-5.45%
Market Cap	3.30B	Forward P/E	-	EPS next Y	-2.60	Insider Trans	4.40%	Shs Float	50.68M	Perf Month	3.88%
Enterprise Value	2.63B	PEG	-	EPS next Q	-0.60	Inst Own	76.88%	Short Float	27.06%	Perf Quarter	18.32%
Income	-151.48M	P/S	1521.88	EPS this Y	-54.47%	Inst Trans	2.08%	Short Ratio	14.49	Perf Half Y	58.31%
Sales	2.17M	P/B	4.66	EPS next Y	-19.27%	ROA	-23.63%	Short Interest	13.71M	Perf YTD	42.75%
Book/sh	8.78	P/C	4.85	EPS next 5Y	-15.30%	ROE	-24.74%	52W High	46.01 -11.02%	Perf Year	21.48%
Cash/sh	8.43	P/FCF	-	EPS past 3/5Y	-61.21% -	ROIC	-21.83%	52W Low	14.80 176.62%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-52.09% -	Gross Margin	29.81%	Volatility	3.96% 5.99%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1211.73	EPS Y/Y TTM	-85.53%	Oper. Margin	-8285.33%	ATR (14)	2.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.74	Sales Y/Y TTM	217.84%	Profit Margin	-6967.99%	RSI (14)	45.86	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	22.79	EPS Q/Q	-113.10%	SMA20	-4.05%	Beta	1.34	Target Price	70.71
Payout	-	Debt/Eq	0.01	Sales Q/Q	3774.42%	SMA50	-2.31%	Rel Volume	0.39	Prev Close	41.61
Employees	113	LT Debt/Eq	0.01	Earnings	Nov 14 BMO	SMA200	33.86%	Avg Volume	946.47K	Price	40.94
IPO	Jan 25, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.97% 2704.71%	Trades		Volume	372,196	Change	-1.61%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-25	Initiated	Wedbush	Outperform	$70
Nov-24-25	Initiated	Truist	Buy
Oct-08-25	Initiated	Guggenheim	Buy	$90
Aug-19-25	Initiated	Piper Sandler	Overweight	$55
Jul-10-25	Resumed	Goldman	Buy	$40
May-02-25	Initiated	JP Morgan	Overweight	$41
Apr-16-25	Initiated	Scotiabank	Sector Perform	$23
Jan-07-25	Initiated	TD Cowen	Buy
Oct-24-24	Initiated	UBS	Buy	$60
Sep-23-24	Initiated	RBC Capital Mkts	Outperform	$66
Aug-28-24	Initiated	ROTH MKM	Buy	$65
Jun-28-24	Initiated	BofA Securities	Buy	$65
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

Show Previous Ratings

Dec-09-25 12:20AM	CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities (Insider Monkey)
Dec-05-25 08:30AM	New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Nov-26-25 07:00AM	CG Oncology Announces New Board Member and Board Transition (GlobeNewswire)
Nov-25-25 04:05PM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting (GlobeNewswire)
Nov-17-25 09:26AM	Company News for Nov 17, 2025 (Zacks)
09:10AM	Loading…
Nov-14-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.61%
08:00AM	CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-25 08:10AM	ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Oct-17-25 09:55PM	CG Oncology (CGON) Gets Initiated With a Buy at Guggenheim (Insider Monkey) +5.14%
Oct-16-25 04:33PM	Guggenheim Initiates CG Oncology (CGON) Coverage with $90 PT, Highlights Bladder Cancer Therapeutic Cretostimogene (Insider Monkey)
Oct-08-25 06:14PM	Why Cg Oncology Stock Rocketed 7% Higher Today (Motley Fool) +7.13% +9.21%
Sep-22-25 03:19AM	CG Oncology (CGON) PT Raised to $79 by Morgan Stanley on Strong Clinical Pipeline for Bladder Cancer Treatment (Insider Monkey)
Sep-19-25 09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
07:00AM	Loading…
Sep-05-25 07:00AM	CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months (GlobeNewswire) +6.88%
Sep-03-25 08:00AM	CG Oncology Completes Enrollment in PIVOT-006 (GlobeNewswire)
Aug-29-25 08:00AM	CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:14AM	CG Oncology's Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut (Insider Monkey)
12:13AM	H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT (Insider Monkey)
Aug-08-25 08:00AM	CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-06-25 08:40AM	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks) -6.12%
Jul-31-25 11:58AM	CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial (Insider Monkey)
Jul-29-25 04:05PM	Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals (GlobeNewswire)
Jul-07-25 08:30AM	Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs (PR Newswire)
Jul-06-25 04:15AM	Morgan Stanley Lifts PT on CG Oncology (CGON) to $56, Keeps an Overweight Rating (Insider Monkey)
Jul-01-25 02:30PM	Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors (PR Newswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
Jun-05-25 08:00AM	CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
08:00AM	Loading…
May-15-25 08:00AM	CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-14-25 09:38AM	Company News for May 14, 2025 (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
07:45AM	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:00AM	SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
Apr-29-25 09:10AM	CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? (Zacks)
02:02AM	Why CG Oncology, Inc. (CGON) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	CG Oncology Soars On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily) +25.03%
11:14AM	CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why (Benzinga)
10:24AM	CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug (Investor's Business Daily)
Apr-26-25 04:10PM	CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting (GlobeNewswire)
Apr-24-25 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 (GlobeNewswire)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +9.36%
Apr-02-25 12:32PM	CG Oncology Looks Attractive At Current Prices (Rating Upgrade) (Seeking Alpha)
Mar-31-25 09:55AM	Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade (Zacks) -7.31%
08:00AM	CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates (GlobeNewswire)
05:54AM	Company News for Mar 31, 2025 (Zacks)
Mar-28-25 07:00AM	CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates (GlobeNewswire)
Mar-26-25 05:45PM	Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? (Insider Monkey)
Mar-24-25 08:00AM	Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy (GlobeNewswire) +5.47%
Mar-12-25 08:00AM	CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates (GlobeNewswire)
Feb-26-25 08:00AM	CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-25-25 09:49AM	Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? (Insider Monkey) -6.65%
Feb-23-25 01:29PM	Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:19PM	Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now (Insider Monkey)
Jan-16-25 09:55AM	Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? (Zacks)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal) +5.35%
Dec-16-24 04:05PM	CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-12-24 08:19PM	CG Oncology Announces Pricing of Public Offering (GlobeNewswire) -9.01%
Dec-11-24 06:17AM	CG Oncology Announces Proposed Public Offering (GlobeNewswire) -5.85%
Dec-06-24 08:00AM	SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award (GlobeNewswire)
07:10AM	CG Oncology announces data from Phase 3 BOND-003 trial (TipRanks)
Dec-05-24 11:35AM	CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate (Benzinga) -6.54%
07:00AM	Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Dec-02-24 08:00AM	CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 (GlobeNewswire)
Nov-20-24 08:00AM	CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting (GlobeNewswire)
Nov-12-24 08:00AM	CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.83%
Nov-11-24 08:00AM	CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer (GlobeNewswire)
Sep-14-24 05:25PM	Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 08:00AM	CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-08-24 08:23AM	CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +7.02%
Jun-18-24 08:00AM	CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec (GlobeNewswire)
Jun-06-24 12:14PM	CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC (GlobeNewswire)
May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76% +5.62%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POST LEONARD E	Director	Nov 17 '25	Option Exercise	0.60	1,000	600	1,000	Nov 18 04:30 PM
POST LEONARD E	Director	Nov 17 '25	Sale	41.43	1,000	41,430	0	Nov 18 04:30 PM
POST LEONARD E	Director	Oct 13 '25	Option Exercise	0.60	1,000	600	1,000	Oct 15 04:15 PM
POST LEONARD E	Director	Oct 13 '25	Sale	43.25	1,000	43,250	0	Oct 15 04:15 PM
Mulay James	Director	Oct 09 '25	Option Exercise	3.72	5,903	21,959	5,903	Oct 10 04:15 PM
Mulay James	Director	Oct 09 '25	Sale	43.99	5,903	259,673	0	Oct 10 04:15 PM
JAMES MULAY	Director	Oct 09 '25	Proposed Sale	40.71	6,557	266,935		Oct 09 04:19 PM
POST LEONARD E	Director	Sep 30 '25	Option Exercise	0.60	5,000	3,000	5,000	Oct 01 05:07 PM
POST LEONARD E	Director	Sep 30 '25	Sale	40.09	5,000	200,450	0	Oct 01 05:07 PM
Mulay James	Director	Sep 29 '25	Option Exercise	1.82	12,755	23,214	12,755	Sep 30 04:38 PM
Mulay James	Director	Sep 29 '25	Sale	39.19	12,755	499,868	0	Sep 30 04:38 PM
LEONARD E POST	Director	Sep 30 '25	Proposed Sale	39.08	5,000	195,400		Sep 30 04:27 PM
Mulay James	Director	Sep 18 '25	Option Exercise	1.82	19,112	34,784	19,112	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Option Exercise	1.82	3,574	6,505	3,574	Sep 22 07:30 AM
Mulay James	Director	Sep 18 '25	Sale	39.01	19,112	745,559	0	Sep 22 07:30 AM
Mulay James	Director	Sep 19 '25	Sale	38.99	3,574	139,350	0	Sep 22 07:30 AM
JAMES MULAY	Director	Sep 18 '25	Proposed Sale	37.72	35,441	1,336,835		Sep 18 04:28 PM
POST LEONARD E	Director	Sep 15 '25	Option Exercise	0.60	1,000	600	1,000	Sep 16 04:15 PM
POST LEONARD E	Director	Sep 15 '25	Sale	35.10	1,000	35,100	0	Sep 16 04:15 PM
LEONARD E POST	Director	Sep 15 '25	Proposed Sale	33.34	3,000	100,020		Sep 15 04:30 PM
Liu Brian Guan-Chyun	Director	Sep 11 '25	Buy	33.00	1,515,151	49,999,983	1,515,151	Sep 15 08:32 AM
Mulay James	Director	Sep 05 '25	Option Exercise	0.60	27,015	16,209	27,015	Sep 08 04:16 PM
Mulay James	Director	Sep 05 '25	Sale	31.53	27,015	851,797	0	Sep 08 04:16 PM
JAMES MULAY	Director	Sep 05 '25	Proposed Sale	30.94	27,015	835,844		Sep 05 04:24 PM
Song Hong Fang	Director	Sep 03 '25	Sale	27.80	100,000	2,779,542	2,903,931	Sep 04 05:00 PM
POST LEONARD E	Director	Sep 03 '25	Option Exercise	0.60	1,000	600	1,000	Sep 04 04:30 PM
POST LEONARD E	Director	Sep 03 '25	Sale	28.00	1,000	28,000	0	Sep 04 04:30 PM
Charming Jade Ltd	Director	Sep 03 '25	Proposed Sale	27.46	100,000	2,746,000		Sep 03 05:06 PM
LEONARD E POST	Director	Sep 03 '25	Proposed Sale	27.46	1,000	27,460		Sep 03 04:29 PM
POST LEONARD E	Director	Jul 17 '25	Option Exercise	0.60	2,000	1,200	2,000	Jul 18 04:30 PM
POST LEONARD E	Director	Jul 17 '25	Sale	28.00	2,000	56,000	0	Jul 18 04:30 PM
LEONARD E POST	Director	Jul 17 '25	Proposed Sale	26.08	2,000	52,160		Jul 17 04:22 PM
POST LEONARD E	Director	May 21 '25	Option Exercise	0.60	1,000	600	1,000	May 22 04:15 PM
POST LEONARD E	Director	May 21 '25	Sale	28.00	1,000	28,000	0	May 22 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Option Exercise	0.60	1,000	600	1,000	Apr 29 04:15 PM
POST LEONARD E	Director	Apr 28 '25	Sale	30.76	1,000	30,760	0	Apr 29 04:15 PM
POST LEONARD E	Director	Mar 17 '25	Option Exercise	0.60	1,000	600	1,000	Mar 18 04:30 PM
POST LEONARD E	Director	Mar 17 '25	Sale	28.00	1,000	28,000	0	Mar 18 04:30 PM
LEONARD E POST	Director	Mar 17 '25	Proposed Sale	27.80	4,000	111,200		Mar 17 04:38 PM
POST LEONARD E	Director	Feb 18 '25	Option Exercise	0.60	1,000	600	1,000	Feb 19 04:15 PM
POST LEONARD E	Director	Feb 18 '25	Sale	28.61	1,000	28,610	0	Feb 19 04:15 PM
POST LEONARD E	Director	Jan 13 '25	Option Exercise	0.60	1,000	600	1,000	Jan 14 04:16 PM
POST LEONARD E	Director	Jan 13 '25	Sale	29.66	1,000	29,660	0	Jan 14 04:16 PM
Song Hong Fang	Director	Dec 16 '24	Sale	28.00	700,000	19,600,000	3,003,931	Dec 17 06:03 PM
POST LEONARD E	Director	Dec 16 '24	Option Exercise	0.60	1,000	600	1,000	Dec 17 05:00 PM
POST LEONARD E	Director	Dec 16 '24	Sale	28.84	1,000	28,840	0	Dec 17 05:00 PM

QURE

uniQure N.V

CGON

Cg Oncology Inc

Upgrade your FINVIZ experience